558 results on '"Kaló, Zoltán"'
Search Results
2. A roadmap towards implementing health technology assessment in Oman
3. Framework for developing cost-effectiveness analysis threshold: the case of Egypt
4. Frailty prevalence in 42 European countries by age and gender: development of the SHARE Frailty Atlas for Europe
5. Consensus-Based Recommendations for the Implementation of Health Technology Assessment in the United Arab Emirates
6. Strategic Approaches to Reducing the Burden of Atopic Dermatitis in the Middle East and Africa Region
7. Maximizing the benefits of using biosimilars in Egypt
8. Incremental cost of premature birth – a public health care payer perspective from Hungary
9. Multistakeholder Perceptions of Additional Value Elements for United States Value Assessment of Health Interventions
10. Systematic Literature Review of Economic Evaluations of Treatment Alternatives in Chronic Lymphocytic Leukemia
11. Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods
12. Humanistic and Economic Burden of Atopic Dermatitis for Adults and Adolescents in the Middle East and Africa Region
13. Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review
14. Health technology assessment in Türkiye: Current status and perspectives on future implementation
15. Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook
16. Patient and Caregiver Experience Decision Factors in Treatment Decision Making: Results of a Systematic Literature Review of Multiple Myeloma Decision Aids
17. Capacity Building for Health Technology Assessment in Jordan: Institutionalization and Its Use in Pricing and Reimbursement Decisions
18. Prioritization of implementation barriers related to integrated care models in Central and Eastern European countries
19. Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?
20. A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt
21. Healthcare financing in Egypt: a systematic literature review.
22. Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers.
23. Regulatory and HTA early dialogues in medical devices
24. Implementation Road Map of Health Technology Assessment in Middle-Income Countries: The Case of Jordan
25. Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges
26. The Role of Patient Experience in the Value Assessment of Complex Technologies – Do HTA Bodies Need to Reconsider How Value is Assessed?
27. Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries
28. Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries
29. Facilitators and Barriers of Incremental Innovation by Fixed Dose Combinations in Cardiovascular Diseases.
30. Development of the Emirates Multi-Criteria Decision Analysis Tool for Orphan Drugs
31. Cost-Effectiveness of Bariatric Surgery in Patients Living with Obesity and Type 2 Diabetes
32. Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings
33. Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives
34. Shedding light on the HTA consultancy market: Insights from Poland
35. External Reference Pricing for Pharmaceuticals—A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage
36. Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016
37. Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology
38. A bariátriai műtétek egészségpolitikai szerepe a 2-es típusú cukorbetegségben szenvedő elhízott betegek ellátásában
39. THE VALUE OF A CHILD BORN IN THE EUROPEAN UNION
40. An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets
41. Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group
42. HTA Implementation in Latin American Countries: Comparison of Current and Preferred Status
43. Implication of external price referencing and parallel trade on pharmaceutical expenditure : indirect evidence from lower-income European countries
44. Recommendations for patient involvement in health technology assessment in Central and Eastern European countries
45. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets
46. Policy objective of generic medicines from the investment perspective: The case of clopidogrel
47. Implementation of palliative care consult Service in Hungary – integration barriers and facilitators
48. Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment
49. Understanding of the Readiness for HTA Implementation in Jordan as a Step Towards Universal Health Coverage
50. Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.